| укр | рус |



No6(2) 2019

Back to the issue

DOI 10.37219/2528-8253-2019-6-37

Kovtunenko OV, Tymchuk SM, Shportko BV
Analysis of expression of molecular marker KI-67 in patients with laryngeal cancer for regional metastases and recurrences
Kovtunenko Alexander Vasilievich
State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine»
Professor of the Department of Otolaryngology
Doctor of Medical Sciences
Orchid ID:

Tymchuk Sergey Nikolaevich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov» Dnipropetrovsk Regional Council
Head of the Department of Otorhinolaryngology No. 2 (oncological)
Doctor of Medical Sciences
Orchid ID:

Shportko Bogdan Viktorovich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov» Dnipropetrovsk Regional Council
Department of Otorhinolaryngology No. 2 (oncological)
Orchid ID:


Background: Laryngeal cancer is a common localization of squamous cell carcinoma of the head and neck. The main factor influencing the survival of patients is the presence of regional metastases. The malignant degeneration of a cell is always accompanied by disruption of the cell cycle, in particular a sharp increase in proliferative activity. The molecular marker Ki-67 is used to investigate the proliferative activity of tumor cells.
Aim of the study: To study the informative content of immunohistochemical investigation and to determine the expression of the molecular marker Ki-67 in patients with laryngeal cancer, prior to the prediction of regional metastasis and relapse.
Materials and Methods: 70 patients with cancer, stage III-IV (T3-4N0-3M0) clinical group II were under observation. Of these, 39 patients from the main group were with regional laryngeal cancer metastases, and 31 patients in the comparison group – without revealed regional metastases. Patients' age ranged from 33 to 74 years. The average age was 61.9 years. Male patients made up the absolute majority of 99% No = 69. All patients were histologically diagnosed with squamous cell carcinoma. Monoclonal antibodies to Ki67 (TermoScientific, USA) were used as the primary molecular markers. The proliferation index (PI) was rated as low in the range of 0-30% and as high in more than 30% of positive cells with an intranuclear label.
Results: The study of molecular markers Ki-67 showed its expression at 69 [60.2; 77.5]% (Me [25%; 75%]) for the squamous cell laryngeal cancer group, without metastases – 60 [29; 70.5]%, for the group with metastases – 72 [67; 80]% (P <0.001).
In statistical data processing, the AUC value (0.777) was set for Ki-67 for metastasis and showed an increased degree of expression for laryngeal cancer metastasis. Ki-67 has a good diagnostic value and can be used as an additional method for predicting regional laryngeal cancer metastases. However the practical use of this marker as a prognostic one for determining the volume of surgery on the lymphatic structures of the neck requires further investigation.
It should be noted that this study did not reveal the link of Ki-67 AUC (0.588) with the degree of differentiation of laryngeal cancer and its recurrence, but more in-depth study of molecular markers in the future may reveal other patterns of tumor growth and be used in the prognosis and personalization of treatment.
Conclusion: Expression of Ki-67 allowed to accurately predict tumor metastasis. A 1% increase in Ki-67 expression resulted in an 8.3% increase in the chance of tumor metastasis (95% CI - 1.043-1.142), and the age dependence on metastasis is not reliable.
Determination of expression of Ki-67 does not accurately predict the possibility of recurrence of laryngeal cancer (p=0.27; AUC (95% CI) – 0.588 (0.414-0.763)) herewith age dependence of chance of a recurrence was not revealed.


laryngeal cancer, metastases, immunohistochemical study, Ki-67.


  1. Bai Y, Shao Y, Li H, Xue W, Quan F, Wu S. Ki67 is over expressed in human laryngeal carcinoma and contributes to the proliferation of HEp2 cells. Oncology Letters. 2016; 12(4): 2641-2647. doi: 10.3892/ol.2016.4980
  2. Barutçu O, Kara M, Muratlı A, Güçlü O, Dereköy S. Clinical significance of Ki-67, c-erbB-2 and E-cadherin expressions in open partial laryngectomy patients. Kulak Burun Bogaz Ihtisas Dergisi. 2016; 26(5): 283-292. doi:10.5606/kbbihtisas.2016.66592.
  3. Barnes L, Eveson J W, Richard P, Sidransky D. World Health Organization Classification of Tumours: pathology and genetics of head and neck tumours. Lyon, France: IARC Press; 2005. 430 p
  4. Bonhin RG, de Carvalho GM, Guimarães AC, Chone CT, Crespo AN, de Almeida Milani Altemani AM, et al. Histologic correlation of expression of Ki-67 in squamous cell carcinoma of the glottis according to the degree of cell differentiation. Brazilian Journal of Otorhinolaryngology. 2014; 80(4): 290-295. doi: 10.1016/j.bjorl.2014.05.016
  5. Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D’Silva N et al. Biomarkers in Advanced Larynx Cancer. Laryngoscope. 2014 Jan; 124(1): 179-87. doi: 10.1002/lary.24245.
  6. De Bree R, Takes RP, Castelijns JA, Medina JE, Stoeckli SJ, Mancuso AA, et al. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head Neck. 2015 Dec; 37(12): 1829-39.
    doi: 10.1002/hed.23814.
  7. De Vincentiis M, Di Cello P, Censi F, Leopizzi M, Natalizi S, Sardella B, et al. Immunohistochemical expression of fatty acid synthase, Ki-67 and p53 in squamous cell carcinomas of the larynx. The International Journal of Biological Markers. 2008; 23(3): 176-81. doi: 10.1177/172460080802300307.
  8. Ferlito A, Rinaldo A, Robbins KT, Leemans CR, Shah JP, Shaha AR, et al. Changing concepts in the surgical management of the cervical node metastasis. Oral Oncol. 2003 Jul; 39(5): 429-35. doi: 10.1016/s1368-8375(03)00010-1.
  9. Gioacchini FM, Alicandri-Ciufelli M, Magliulo G, Rubini C, Presutti L, Re M. The clinical relevance of Ki-67 expression in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2015 Jul; 272(7): 1569-76.
    doi: 10.1007/s00405-014-3117-0.
  10. Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol. 2012; 48(3):
    203-10. doi: 10.1016/j.oraloncology.2011.10.015.
  11. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J. Cancer. 2013; 4: 66-83. doi: 10.7150/jca.5112
  12. Kulagin RN. [Molecular prognostic markers of lymphogenous metastasis of squamous cell carcinoma of the larynx (an immuno-histochemical study)]. Vestn Otorinolaringol. 2011;(5):11-4. [Article in Russian].
  13. Li DW, Sun YJ, Sun ZF, Dong P. Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma. J Laryngol Otol. 2012 Nov; 126(11): 1127-33. doi: 10.1017/S0022215112001971.
  14. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Annals of Oncology. 2004; 15(9): 1319-29. doi: 10.1093/annonc/mdh299.
  15. Re M, Zizzi A, Ferrante L, Stramazzotti D, Goteri G, Gioacchini FM, et al. p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival. Eur Arch Otorhinolaryngol. 2014 Jun; 271(6): 1641-51.
    doi: 10.1007/s00405-013-2833-1.
  16. Robbins KT, Ferlito A, Shah JP, Hamoir M, Takes RP, Strojan P, et al. The evolving role of selective neck dissection for head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2013 Mar; 270(4): 1195-202.
    doi: 10.1007/s00405-012-2153-x.
  17. Vukelic J, Dobrila-Dintinjana R, Dekanic A, Marijic B, Cubranic A, Braut T. The relevance of assessing the cell proliferation factor ki-67 in squamous cell carcinoma of the larynx. Biomed. Res. Int. 2019; 2019: 8142572.
    doi: 10.1155/2019/8142572.

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»